Extracellular acidification-induced CXCL8 production through a proton-sensing receptor OGR1 in human airway smooth muscle cells: a response inhibited by dexamethasone.

Airway smooth muscle cell Bronchial asthma COPD CXCL8 Dexamethasone NF-κB OGR1 Proton

Journal

Journal of inflammation (London, England)
ISSN: 1476-9255
Titre abrégé: J Inflamm (Lond)
Pays: England
ID NLM: 101232234

Informations de publication

Date de publication:
2019
Historique:
received: 11 09 2018
accepted: 27 01 2019
entrez: 5 3 2019
pubmed: 5 3 2019
medline: 5 3 2019
Statut: epublish

Résumé

Human airway smooth muscle cells (ASMCs) contribute to bronchial contraction and airway hyperresponsiveness in patients with bronchial asthma. They also generate cytokines, chemokines, and matricellular proteins. Ovarian cancer G protein-coupled receptor 1 (OGR1) senses extracellular protons and mediates the production of interleukin-6 (IL-6) and connective tissue growth factor (CTGF) in ASMCs. ASMCs were stimulated for the indicated time by pH 6.3 or pH 7.4-adjusted Dulbecco's Modified Eagle Medium (DMEM) containing 0.1% bovine serum albumin (BSA) (0.1% BSA-DMEM). As a control stimulant, pH 7.4-adjusted 0.1% BSA-DMEM containing 10 ng/mL tumor necrosis factor-α (TNF-α) was used. Interleukin-8/C-X-C motif chemokine ligand 8 (CXCL8) mRNA expression in ASMCs was quantified by RT-PCR using real-time TaqMan technology. CXCL8 secreted from ASMCs was measured by enzyme-linked immunosorbent assay (ELISA). Phosphorylation at serine 536 of NF-κB p65 and binding of p65 to oligonucleotide containing an NF-κB consensus binding site were analyzed by Western blotting and an ELISA-based kit. Acidic pH induced a significant increase of CXCL8 mRNA expression and CXCL8 protein secretion in ASMCs. ASMCs transfected with small interfering RNA (siRNA) targeted for OGR1 produced less CXCL8 compared with those transfected with non-targeting siRNA. Protein kinase C (PKC) inhibitor, MEK1/2 inhibitor, and the inhibitor of IκB phosphorylation reduced acidic pH-stimulated CXCL8 production in ASMCs. Dexamethasone also inhibited acidic pH-stimulated CXCL8 production of ASMCs in a dose-dependent manner. Dexamethasone did not affect either phosphorylation or binding to the consensus DNA site of NF-κB p65. CXCL8 released from ASMCs by extracellular acidification may play a pivotal role in airway accumulation of neutrophils. Glucocorticoids inhibit acidic pH-stimulated CXCL8 production independent of serine 536 phosphorylation and the binding to DNA of NF-κB p65, although NF-κB activity is essential for CXCL8 production in ASMCs.

Sections du résumé

BACKGROUND BACKGROUND
Human airway smooth muscle cells (ASMCs) contribute to bronchial contraction and airway hyperresponsiveness in patients with bronchial asthma. They also generate cytokines, chemokines, and matricellular proteins. Ovarian cancer G protein-coupled receptor 1 (OGR1) senses extracellular protons and mediates the production of interleukin-6 (IL-6) and connective tissue growth factor (CTGF) in ASMCs.
METHODS METHODS
ASMCs were stimulated for the indicated time by pH 6.3 or pH 7.4-adjusted Dulbecco's Modified Eagle Medium (DMEM) containing 0.1% bovine serum albumin (BSA) (0.1% BSA-DMEM). As a control stimulant, pH 7.4-adjusted 0.1% BSA-DMEM containing 10 ng/mL tumor necrosis factor-α (TNF-α) was used. Interleukin-8/C-X-C motif chemokine ligand 8 (CXCL8) mRNA expression in ASMCs was quantified by RT-PCR using real-time TaqMan technology. CXCL8 secreted from ASMCs was measured by enzyme-linked immunosorbent assay (ELISA). Phosphorylation at serine 536 of NF-κB p65 and binding of p65 to oligonucleotide containing an NF-κB consensus binding site were analyzed by Western blotting and an ELISA-based kit.
RESULTS RESULTS
Acidic pH induced a significant increase of CXCL8 mRNA expression and CXCL8 protein secretion in ASMCs. ASMCs transfected with small interfering RNA (siRNA) targeted for OGR1 produced less CXCL8 compared with those transfected with non-targeting siRNA. Protein kinase C (PKC) inhibitor, MEK1/2 inhibitor, and the inhibitor of IκB phosphorylation reduced acidic pH-stimulated CXCL8 production in ASMCs. Dexamethasone also inhibited acidic pH-stimulated CXCL8 production of ASMCs in a dose-dependent manner. Dexamethasone did not affect either phosphorylation or binding to the consensus DNA site of NF-κB p65.
CONCLUSIONS CONCLUSIONS
CXCL8 released from ASMCs by extracellular acidification may play a pivotal role in airway accumulation of neutrophils. Glucocorticoids inhibit acidic pH-stimulated CXCL8 production independent of serine 536 phosphorylation and the binding to DNA of NF-κB p65, although NF-κB activity is essential for CXCL8 production in ASMCs.

Identifiants

pubmed: 30828266
doi: 10.1186/s12950-019-0207-1
pii: 207
pmc: PMC6381743
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4

Déclaration de conflit d'intérêts

Not applicable.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Références

J Interferon Cytokine Res. 1999 May;19(5):429-38
pubmed: 10386854
Allergy. 1999 Jul;54(7):691-9
pubmed: 10442524
Am J Respir Crit Care Med. 2000 Mar;161(3 Pt 1):694-9
pubmed: 10712309
Clin Exp Allergy. 2000 Jun;30 Suppl 1:54-9
pubmed: 10849477
Am J Respir Cell Mol Biol. 2000 Jul;23(1):79-85
pubmed: 10873156
Mol Cell Biol. 2000 Sep;20(18):6891-903
pubmed: 10958685
Chest. 2001 May;119(5):1329-36
pubmed: 11348936
J Allergy Clin Immunol. 2003 Jan;111(1 Suppl):S18-34; discussion S34-6
pubmed: 12532084
Nature. 2003 Sep 4;425(6953):93-8
pubmed: 12955148
J Allergy Clin Immunol. 2004 Apr;113(4):610-9
pubmed: 15100663
J Allergy Clin Immunol. 2004 Aug;114(2 Suppl):S32-50
pubmed: 15309017
Inflamm Res. 2004 Dec;53(12):664-9
pubmed: 15654514
Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2103-11
pubmed: 15980040
J Heart Lung Transplant. 2005 Jul;24(7):875-81
pubmed: 15982617
Cell Signal. 2005 Dec;17(12):1466-76
pubmed: 16014326
J Allergy Clin Immunol. 2005 Sep;116(3):544-9
pubmed: 16159622
J Exp Med. 2006 Jan 23;203(1):7-13
pubmed: 16380507
Respir Med. 2006 Sep;100(9):1614-22
pubmed: 16448811
Respir Res. 2006 May 03;7:71
pubmed: 16670028
Am J Respir Crit Care Med. 2007 May 1;175(9):905-10
pubmed: 17290044
N Engl J Med. 2007 Mar 29;356(13):1327-37
pubmed: 17392302
Life Sci. 2007 Sep 8;81(13):1094-102
pubmed: 17869310
Am J Respir Crit Care Med. 2007 Dec 15;176(12):1185-91
pubmed: 17901415
J Immunol. 2007 Nov 1;179(9):5686-92
pubmed: 17947640
Annu Rev Physiol. 2009;71:509-35
pubmed: 18851708
Pulm Pharmacol Ther. 2009 Oct;22(5):353-9
pubmed: 19121407
Eur J Pharmacol. 2009 Mar 1;605(1-3):15-22
pubmed: 19171135
Curr Opin Pharmacol. 2009 Jun;9(3):243-9
pubmed: 19269247
Eur Respir J. 2009 Dec;34(6):1436-43
pubmed: 19460789
Am J Respir Crit Care Med. 2010 Jan 15;181(2):116-24
pubmed: 19815809
Korean J Physiol Pharmacol. 2008 Aug;12(4):171-6
pubmed: 19967052
Respir Res. 2010 Jul 13;11:95
pubmed: 20626862
Am J Physiol Lung Cell Mol Physiol. 2010 Oct;299(4):L567-77
pubmed: 20656891
Am J Respir Cell Mol Biol. 2011 Nov;45(5):984-90
pubmed: 21493783
Biochem Biophys Res Commun. 2011 Oct 7;413(4):499-503
pubmed: 21907704
Am J Physiol Lung Cell Mol Physiol. 2012 Aug 1;303(3):L272-8
pubmed: 22523282
Respirology. 2012 Aug;17(6):997-1005
pubmed: 22616553
Pulm Pharmacol Ther. 2013 Feb;26(1):64-74
pubmed: 22634303
Int Endod J. 2013 Feb;46(2):128-36
pubmed: 22788664
J Allergy Clin Immunol. 2012 Oct;130(4):877-85.e5
pubmed: 22947346
Inflammation. 2013 Jun;36(3):616-24
pubmed: 23264166
Mol Cell Endocrinol. 2013 Nov 5;380(1-2):41-54
pubmed: 23267834
PLoS One. 2012;7(12):e51847
pubmed: 23300567
J Allergy (Cairo). 2013;2013:185971
pubmed: 23577039
Mol Pharmacol. 2013 Oct;84(4):488-500
pubmed: 23880553
Cell Signal. 2013 Nov;25(11):2263-71
pubmed: 23917207
Nat Rev Drug Discov. 2013 Jul;12(7):543-59
pubmed: 23977698
PLoS One. 2013 Dec 05;8(12):e81494
pubmed: 24339939
Mediators Inflamm. 2014;2014:712962
pubmed: 25197168
Am J Respir Crit Care Med. 2015 Jan 1;191(1):54-62
pubmed: 25411910
Am J Respir Cell Mol Biol. 2016 Jun;54(6):792-801
pubmed: 26574643
Am J Physiol Lung Cell Mol Physiol. 2016 Jan 15;310(2):L202-11
pubmed: 26589477
Sci Rep. 2016 Apr 14;6:24552
pubmed: 27076368
Sci Rep. 2016 May 11;6:25765
pubmed: 27166427
Lancet Respir Med. 2016 Oct;4(10):797-806
pubmed: 27574788
J Allergy Clin Immunol. 2017 Apr;139(4):1176-1185
pubmed: 27609656
Am J Respir Cell Mol Biol. 2017 Apr;56(4):532-538
pubmed: 27997807
Sci Rep. 2017 Mar 23;7:44951
pubmed: 28332558
Int Arch Allergy Immunol. 2018;176(2):83-90
pubmed: 29649811
Clin Exp Immunol. 1997 Apr;108(1):95-104
pubmed: 9097917
J Biol Chem. 1997 Aug 22;272(34):21096-103
pubmed: 9261113
Chest. 1997 Aug;112(2):505-10
pubmed: 9266891
J Immunol. 1998 Sep 1;161(5):2509-15
pubmed: 9725250

Auteurs

Maiko Kadowaki (M)

1Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193 Japan.

Hidenori Yamada (H)

2Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebeshi, 371-8511 Japan.

Koichi Sato (K)

3Laboratory of Signal Transduction, Institute for Molecular and Cellular Regulation, Gunma University, 3-39-15 Showa-machi, Maebeshi, 371-8511 Japan.

Hiroko Shigemi (H)

1Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193 Japan.

Yukihiro Umeda (Y)

1Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193 Japan.

Miwa Morikawa (M)

1Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193 Japan.

Yuko Waseda (Y)

1Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193 Japan.

Masaki Anzai (M)

1Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193 Japan.

Yosuke Kamide (Y)

2Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebeshi, 371-8511 Japan.

Haruka Aoki-Saito (H)

2Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebeshi, 371-8511 Japan.

Takeshi Hisada (T)

2Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebeshi, 371-8511 Japan.

Fumikazu Okajima (F)

4Laboratory of Signal Transduction, Faculty of Pharmaceutical Sciences, Aomori University, 2-3-1 Kobata, Aomori, 030-0943 Japan.

Tamotsu Ishizuka (T)

1Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, 23-3 Matsuoka-Shimoaizuki, Eiheiji, Fukui, 910-1193 Japan.

Classifications MeSH